Company Filing History:
4 out of 13 
1 out of 15 Years Active: 2024-2025
Title: Tielin Zhou: Innovator in Tumor Immunotherapy
Introduction
Tielin Zhou is a prominent inventor based in Singapore, known for his significant contributions to the field of tumor immunotherapy. With a total of 4 patents, Zhou has developed innovative solutions aimed at enhancing the efficacy of cancer treatments.
Latest Patents
Zhou's latest patents include groundbreaking inventions such as the "Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof." This invention relates to a bispecific antibody that effectively blocks two mechanisms of tumor immune escape, thereby improving outcomes in tumor immunotherapy. Another notable patent is the "Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof." This humanized antibody has high affinity for OX40 and stimulates T cells to secrete cytokines, facilitating positive immune regulation and enhancing the immune response against tumors.
Career Highlights
Throughout his career, Tielin Zhou has worked with esteemed companies such as Nanjing Genscript Biotech Co., Ltd. and Nanjing Legend Biotech Co., Ltd. His work in these organizations has contributed to advancements in biotechnological applications and therapeutic developments.
Collaborations
Zhou has collaborated with notable colleagues, including Liusong Yin and Zhuo Fang, further enriching his research and development efforts in the field of immunotherapy.
Conclusion
Tielin Zhou's innovative work in tumor immunotherapy, highlighted by his recent patents, showcases his commitment to advancing cancer treatment. His contributions are paving the way for more effective therapeutic strategies in the fight against cancer.